Veracyte (VCYT) Osake Kurssi

Veracyte Inc is primarily active in the industry of molecular diagnostics.

The main competitors of Veracyte Inc in the market are companies like Genomic Health Inc, Myriad Genetics Inc, and NanoString Technologies Inc.

Veracyte Inc. is a renowned molecular diagnostics company with a rich history and background. Founded in 2008, Veracyte has been dedicated to improving patient outcomes by providing genomic testing solutions. Based in South San Francisco, California, the company combines advanced genomic technology with machine learning to deliver accurate and reliable diagnostic information to physicians and patients. Veracyte's innovative products, such as the Afirma Genomic Sequencing Classifier and Percepta Bronchial Genomic Classifier, have revolutionized the diagnosis of thyroid and lung cancers. Veracyte Inc. has grown rapidly over the years and continues to make significant contributions to the field of molecular diagnostics, benefiting countless patients and healthcare professionals alike.

Veracyte Inc has achieved significant milestones since its establishment. Notably, the company successfully launched the Afirma Genomic Sequencing Classifier, a groundbreaking diagnostic test used to detect thyroid cancer with high accuracy. Veracyte also received approval from the U.S. Food and Drug Administration (FDA) for its Percepta Bronchial Genomic Classifier, a test aiding in the diagnosis of lung cancer. Furthermore, the company expanded its product portfolio by introducing the Envisia Genomic Classifier, utilized for diagnosing idiopathic pulmonary fibrosis (IPF). Veracyte's commitment to innovative genomics and precision medicine has positioned itself as an industry leader, revolutionizing molecular diagnostic solutions for improved patient care.

Veracyte Inc primarily operates in the United States.

Veracyte Inc represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on improving patient outcomes, the company combines cutting-edge genomic diagnostic solutions with machine learning to deliver accurate and actionable results. Veracyte Inc is committed to empowering physicians with reliable and timely information, helping them make informed decisions about patient care. The company's dedication to research and development ensures the continuous improvement of its products, leading to better diagnostic accuracy and personalized treatment options. Through its commitment to excellence and patient advocacy, Veracyte Inc is transforming the field of diagnostics and improving healthcare outcomes.

Analyytikot asettavat tällä hetkellä Veracyte-osakkeelle keskimääräisen tavoitehinnan 55,57 USD (mediaani: 54,00 USD), mikä merkitsee +28,8 % viimeisimpään hintaan verrattuna. Konsensus perustuu 19 analyytikkoarvioon.

Veracyte Analyytikkojen kursstavoitteet 2026

19 analyytikkoa arvioi tällä hetkellä Veracyte-osaketta: 16 suosittaa ostoa, 2 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Veracyte-yhtiöltä 593,79 M USD liikevaihtoa ja 1,89 USD osakekohtaista tulosta.

Veracyte Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Veracyte-osake noteerataan hintaan 38,54 EUR (43,16 USD).

Veracyte-osake (VCYT) on listattuna 4 pörssissä, muun muassa: NASDAQ (VCYT), Frankfurt (12V.F), München (12V.MU), Düsseldorf (12V.DU).

Veracyte Inc. is an emerging company specializing in the development of innovative diagnostic tests for cancer. The company's business model relies on a combination of technological innovation, close collaboration with medical professionals, and a strong distribution strategy. The products of Veracyte Inc. are designed to enable better diagnosis and therapy for cancer, thereby increasing the chances of cure. The company focuses on three main areas: endocrinology, lung cancer, and mesothelioma. Within endocrinology, Veracyte Inc. offers an innovative diagnostic procedure for thyroid nodules called the "Afirma Test," which allows for accurate differentiation between benign and malignant nodules without the need for surgery. This enables doctors to recommend targeted, non-invasive therapy and avoid unnecessary operations. In the field of lung cancer, the company has developed the "Percepta" test, which enables non-invasive diagnosis of lung cancer. The test uses RNA sequencing and analysis of protein content in lung fluid to make an accurate diagnosis of cancer cells. This allows for early diagnosis of lung cancer, increasing the chances of cure and avoiding unnecessary investigations and operations. The third area, mesothelioma, focuses on a rare form of cancer caused by asbestos exposure. Here, Veracyte Inc. offers the "Envisia" test, which enables accurate diagnosis of mesothelioma. The test uses specific markers and RNA sequencing to make an accurate diagnosis. Veracyte Inc. works closely with medical professionals and clinics to increase the acceptance and dissemination of its products. The company relies on a targeted distribution strategy and a strong online presence. By implementing targeted marketing and training for healthcare professionals and creating awareness among patients, the aim is to achieve broad acceptance of the products. In summary, the business model of Veracyte Inc. is based on the development of innovative diagnostic tests for various types of cancer. By collaborating closely with medical professionals and implementing a targeted distribution strategy, the company aims to increase the acceptance and dissemination of its products. The company is committed to increasing the chances of cure for cancer patients and avoiding unnecessary investigations and operations.

odotettu liikevaihto Veracyte on 593,79 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Veracyte on 154,22 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Veracyte:n hinta-voitto-suhde (P/E) on tällä hetkellä 22,78. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Veracyte-osakkeen arvostusta.

Veracyte:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,92. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Veracyte-osakkeen arvostuskennuslukuna.

Veracyte:n Eulpool-laatuscore on 6/10.

Veracyte:n ISIN on US92337F1075. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Veracyte:n WKN on A1W7EA. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Veracyte:n ticker on VCYT. Tämä pörssinoteeraus käytetään Veracyte-osakkeiden kauppaan pörssissä.